Venlafaxine
Venlafaxine has been studied in 18 papers since 2016: 5 trials and 5 observational studies in people, 1 in animals, 7 reviews; 10 in the past year. It is an approved medicine. The newest paper, Oct 30, 2026: “Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis”.
1 new paper in 30 daysSee all 27 papers on venlafaxine
At a glance
The findings reach people, from one lab or study. 5 independent labs in 3 countries; 91 trials, none about aging, 42 with no results posted.
“Venlafaxine did not affect serum concentrations of tamoxifen or its metabolites.”
None of its findings points the other way.
- 5 independent labs in 3 countries
- 91 trials, none about aging, 42 with no results posted
- Funders: China Pharmaceutical University and others
- Human trial5
- Humans5
- Animals1
Studies in people
1 study gave venlafaxine to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases hot flash score-49.8% (P < 0.001) no change: Has no effect on tamoxifen | Trial4 weeks | 17 peopleWomenPatient cohorts | Breast cancer (Tokyo, Japan), Feb 5, 2026 |
What did studies of venlafaxine find?
8Studies of venlafaxine measured 8 outcomes, among them vasomotor symptoms, depressive symptoms and tamoxifen.
Vasomotor symptoms
downin humans1
1 study
Vasomotor symptoms
downin humans1
Venlafaxine decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -0.42, 95% CI -0.76 to -0.07).
“venlafaxine 75 mg (SMD -0.42, 95% CI -0.76 to -0.07)”
Reviewbreast cancer-related vasomotor symptoms; compared with placebo75 mgfemales
Frontiers in pharmacology
Depressive symptoms
downin humans1
1 study
Depressive symptoms
downin humans1
Venlafaxine decreases depressive symptoms in patients with major depressive disorder.
“Escitalopram and venlafaxine effectively manage depressive symptoms and vasomotor instability in patients with major depressive disorder.”
Reviewin patients with major depressive disorderfemales
FIGO best practice recommendations for the mental health of women at menopausal age
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Tamoxifen
no changein humans1
1 study
Tamoxifen
no changein humans1
Venlafaxine showed no clear effect on tamoxifen in humans.
“Venlafaxine did not affect serum concentrations of tamoxifen or its metabolites.”
Human trial37.5 mg/day4 weeksfemalesn = 18
Breast cancer (Tokyo, Japan)
Hot flash score
downin humans1
1 study
Hot flash score
downin humans1
Venlafaxine decreases hot flash score in humans (-49.8% (P < 0.001)).
“At Week 4, hot flash scores declined by 49.8% from baseline (P < 0.001).”
Human trial37.5 mg/day4 weeksfemalesn = 17
Breast cancer (Tokyo, Japan)
PI3K–AKT signaling
upin animals1
1 study
PI3K–AKT signaling
upin animals1
Venlafaxine activates PI3K–AKT signaling.
“venlafaxine upregulated cortical catechol-O-methyltransferase expression and activity via activating phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway”
Animalscerebral cortex
Drug metabolism and disposition: the biological fate of chemicals
S-adenosylmethionine
downin animals1
1 study
S-adenosylmethionine
downin animals1
Venlafaxine decreases S-adenosylmethionine (chronic in vivo exposure).
“decreases in the methyl donor S-adenosylmethionine (SAM) levels”
Animalschronic in vivo exposurecerebral cortex8 days
Drug metabolism and disposition: the biological fate of chemicals
Catechol-O-methyltransferase
upin animals1
1 study
Catechol-O-methyltransferase
upin animals1
Venlafaxine increases catechol-O-methyltransferase (chronic in vivo exposure).
“Chronic in vivo exposure to venlafaxine for 8 days led to increases in cerebral COMT expression and activity”
Animalschronic in vivo exposurecerebral cortex8 days
Drug metabolism and disposition: the biological fate of chemicals
Alzheimer's disease progression
downin humans1HR 0.72
1 study
Alzheimer's disease progression
downin humans1HR 0.72
Venlafaxine is linked with lower alzheimer's disease progression in humans (mild cognitive impairment) (HR 0.72 [0.62, 0.85]).
“venlafaxine (vs. escitalopram: difference: ‐0.04 [‐0.07, ‐0.02], P=0.002, HR: 0.72 [0.62, 0.85], P<0.001)”
Humansmild cognitive impairment
AAIC 2025 abstract
What is venlafaxine linked with?
1Studies link venlafaxine with Alzheimer's disease.
Alzheimer's disease
downin humans1HR 0.72
1 study
Alzheimer's disease
downin humans1HR 0.72
Venlafaxine is linked with a lower risk of Alzheimer's disease in humans (active comparator vs escitalopram, MCI cohort) (HR 0.72, 95% CI 0.62–0.84).
“venlafaxine (vs escitalopram; 0.72, 95% CI [0.62, 0.84])”
Humansactive comparator vs escitalopram, MCI cohort
Alzheimer's & dementia (New York, N. Y.)
Has venlafaxine been tested in people?
0 of 91 about agingYes: 5 trials and 5 observational studies in people have been published, and 91 trials are registered.
Approved
Dec 28, 1993Discontinued
Oct 20, 1997Depressive Disorder, Major, Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder
May 20, 2008Depressive Disorder, Major, Phobia, Social, Social Anxiety Disorder, major depressive episode
Jun 29, 2022Depressive Disorder, Major, Generalized Anxiety Disorder
Repurposing
Phase 3Terminated1 trial
Phase 4Results posted31 trials
Phase 4Completed1 trial
Phase 4Results posted2 trials
Phase 4Terminated1 trial
Phase 4Results posted1 trial
All 38Fewer
In trials
Roux-en-y gastric bypass
Phase 4Completed2 trials
Obstructive sleep apnea of adult
Phase 4Completed1 trial
Physiological sexual dysfunction
Phase 4Completed1 trial
Sleeve gastrectomy
Phase 4Completed1 trial
Prostatic neoplasm
Phase 3Terminated2 trials
Bariatric surgery
Phase 1Completed1 trial
Stopped
NCT01436643TerminatedDepression
Due to slow enrollment the study was terminated early
NCT00354432TerminatedHot flashes
Stopped by the DSMB for lack of effect per interim stopping rule.
NCT05603104TerminatedSchizophrenia
The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00.
NCT00211809Terminated
low enrollment
Who is developing venlafaxine?
1 company: Teva Pharmaceuticals USA.
- Companies
- Teva Pharmaceuticals USAPhase 1
Trial sponsors
Company10 trialsPhase 43,935 people
Company4 trialsPhase 41,840 people
Company1 trialPhase 4347 people
HolsboerMaschmeyer NeuroChemie
Company1 trialPhase 480 people
Novartis Pharmaceuticals Corporation
Company1 trialPhase 454 people
Company4 trialsPhase 31,032 people
Company1 trialPhase 32,944 people
Janssen Research & Development
Company1 trialPhase 3802 people
Funding
1 grant since 2022National Institute for Health Research£2M
Contains public sector information licensed under the Open Government Licence v3.0.